Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$20.8 million.

  • Orchestra BioMed Holdings' Profit After Tax fell 3501.88% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 3018.7%. This contributed to the annual value of -$61.0 million for FY2024, which is 2423.45% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Profit After Tax stood at -$20.8 million, which was down 3501.88% from -$19.4 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Profit After Tax registered a high of -$5.7 million during Q1 2022, and its lowest value of -$20.8 million during Q3 2025.
  • In the last 4 years, Orchestra BioMed Holdings' Profit After Tax had a median value of -$13.3 million in 2023 and averaged -$13.5 million.
  • In the last 5 years, Orchestra BioMed Holdings' Profit After Tax plummeted by 9095.83% in 2023 and then plummeted by 1584.56% in 2024.
  • Over the past 4 years, Orchestra BioMed Holdings' Profit After Tax (Quarter) stood at -$9.8 million in 2022, then tumbled by 31.47% to -$12.8 million in 2023, then dropped by 26.03% to -$16.2 million in 2024, then decreased by 28.93% to -$20.8 million in 2025.
  • Its Profit After Tax stands at -$20.8 million for Q3 2025, versus -$19.4 million for Q2 2025 and -$18.8 million for Q1 2025.